Masimo (MASI) Stock Price, News & Analysis

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MASI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MASI, but not buy additional shares or sell existing shares.
View MASI analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 1-year target prices for Masimo's stock. Their MASI share price targets range from $86.00 to $170.00. On average, they predict the company's share price to reach $137.43 in the next year. This suggests a possible upside of 0.6% from the stock's current price.
View analysts price targets for MASI or view top-rated stocks among Wall Street analysts.

Masimo's stock was trading at $117.21 on January 1st, 2024. Since then, MASI shares have increased by 16.6% and is now trading at $136.62.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MASI earnings forecast.

Masimo Co. (NASDAQ:MASI) issued its quarterly earnings results on Tuesday, February, 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.82 by $0.43. The medical equipment provider had revenue of $548.90 million for the quarter, compared to analysts' expectations of $545.69 million. Masimo had a net margin of 3.98% and a trailing twelve-month return on equity of 13.77%. Masimo's revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share.

ETFs with the largest weight of Masimo (NASDAQ:MASI) stock in their portfolio include Simplify Health Care ETF (PINK), Fidelity Disruptive Medicine ETF (FMED), First Trust Indxx Medical Devices ETF (MDEV), Global X Telemedicine & Digital Health ETF (EDOC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), BlackRock Future Health ETF (BMED), SPDR S&P Health Care Equipment ETF (XHE) and Harbor Health Care ETF (MEDI).

Masimo issued an update on its first quarter 2024 earnings guidance on Wednesday, April, 17th. The company provided EPS guidance of 0.670-0.740 for the period, compared to the consensus EPS estimate of 0.690. The company issued revenue guidance of $476.0 million-$501.0 million, compared to the consensus revenue estimate of $487.6 million.

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

Masimo's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.03%), Juncture Wealth Strategies LLC (0.00%) and Riverview Trust Co (0.00%). Insiders that own company stock include Adam Mikkelson, Joe E Kiani, Micah W Young and Tao Levy.
View institutional ownership trends.

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.